Study of IB-FOLFIRI for advanced colon cancer with BRAF V600E mutation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (IB-FOLFIRI) for people with metastatic colorectal cancer that has a specific gene change called BRAF V600E. It is for those whose cancer has grown after at least one prior treatment and who have not had irinotecan stop working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer has a specific change in the BRAF gene (BRAF V600E), found by a tissue biopsy or a blood test (ctDNA).
- Your cancer has gotten worse after at least one previous treatment, such as FOLFOX/XELOX with or without bevacizumab, or FOLFOXIRI with or without bevacizumab.
- You have not had irinotecan stop working for you before (your cancer did not get worse while on it or within 3 months after stopping).
- You are in good overall health (able to care for yourself, with normal blood, kidney, and liver function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with advanced colorectal cancer that has a specific genetic change called BRAF V600E. The treatment includes a targeted therapy (ivosidenib) plus chemotherapy and a pain-relief drug (celecoxib). It is for people whose cancer has stopped responding to previous treatments, including BRAF-targeted therapies.
This trial tests a combination of drugs for people with advanced colorectal cancer that has worsened after first treatment. It aims to see if this new mix can help control the cancer better.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
This study tests a new combination of drugs (an immunotherapy called QL1706 plus bevacizumab and standard chemotherapy) as a first-line treatment for people with advanced colorectal cancer that has a BRAF V600E mutation. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) plus bevacizumab and chemotherapy as a first treatment for advanced colorectal cancer. The goal is to see if this combination can shrink tumors and help you live longer.
Hear when a new BRAF V600 Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.